fenofibric acid has been researched along with Dyslipidemia in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 24 (72.73) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Han, JS; Hwang, GS; Jung, Y; Kim, K; Lee, HY; Lee, JH; Lee, SH; Namgung, J; Suh, J | 1 |
| Ballantyne, CM; Barbalic, M; Belmont, J; Brautbar, A; Chen, F; Hegele, RA; Scherer, S; Virani, SS | 1 |
| Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA | 1 |
| Joshi, PH; Lele, A; Rinehart, S; Sharma, A; Thakker, KM; Voros, S | 1 |
| Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Keating, GM; Yang, LP | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Hilleman, DE; Maciejewski, SR; Mohiuddin, SM; Schima, SM; Williams, MA | 1 |
| Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM | 1 |
| Elisaf, MS; Kei, A; Milionis, HJ; Moutzouri, E | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Campbell, J; Mohiuddin, SM | 1 |
| Carlson, DM; Hirshberg, B; Kelly, MT; Rosenson, RS; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Bittner, V; Goldberg, AC; Kelly, MT; Lele, A; Pepine, CJ; Setze, CM; Sleep, DJ; Thakker, K | 1 |
| Bielecka, A; Bułdak, Ł; Duława-Bułdak, A; Krysiak, R; Madej, A; Okopień, B; Łabuzek, K | 1 |
| Ballantyne, CM; Belmont, J; Brautbar, A; Jones, PH; Nambi, V; Virani, SS | 1 |
| Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM | 1 |
| Filippatos, TD | 1 |
| Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
6 review(s) available for fenofibric acid and Dyslipidemia
| Article | Year |
|---|---|
Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Delayed-Action Preparations; Drug Delivery Systems; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2010 |
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic | 2010 |
The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Topics: Choline; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2010 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Creatine Kinase; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Randomized Controlled Trials as Topic; Triglycerides | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
18 trial(s) available for fenofibric acid and Dyslipidemia
| Article | Year |
|---|---|
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Lipid Metabolism; Male; Middle Aged | 2018 |
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult | 2013 |
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2014 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Puerto Rico; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Young Adult | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Topics: Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Treatment Outcome | 2011 |
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Topics: Apolipoprotein C-III; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Polymorphism, Single Nucleotide; Regression Analysis; Triglycerides | 2012 |
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
9 other study(ies) available for fenofibric acid and Dyslipidemia
| Article | Year |
|---|---|
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
Topics: Amino Acids; Apolipoprotein A-I; Apolipoprotein A-V; Apolipoproteins A; Cholesterol, HDL; Dyslipidemias; Female; Fenofibrate; Genetic Variation; Humans; Male; Promoter Regions, Genetic; Triglycerides | 2013 |
Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia.
Topics: Analysis of Variance; Biomarkers; Cholesterol, VLDL; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Linear Models; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Fenofibric Acid (trilipix).
Topics: Coronary Disease; Drug Approval; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; United States | 2009 |
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PPAR alpha | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
Topics: Adipocytes; Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; In Vitro Techniques; Intra-Abdominal Fat; Male; Middle Aged; Pyrroles; Subcutaneous Fat | 2011 |